 After looking at interim phase 2b data, Enanta Pharmaceuticals Inc NASDAQ: ENTA has decided to stop the monotherapy trial of EDP-305 for non-alcoholic steatohepatitis NASH. Instead, Enanta now plans to prioritize combination approaches through out-licensing arrangements. 